SAN DIEGO, June 29, 2020 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that the U.S. Food and Drug Administration (FDA) has approved Roche's Phesgo™ (pertuzumab, ...

Nucala (mepolizumab) is a brand-name subcutaneous injection that comes in different forms. Depending on which form you’re prescribed, you or your doctor will administer the injection. Nucala injection ...

Subcutaneous administration is preferred by patients, physicians and healthcare providers, and is associated with a reduction in healthcare costs1,2,3 Treatment with Phesgo is over 90% faster, ...

Credit: Braeburn. Brixadi (weekly) and Brixadi (monthly) are different formulations. Brixadi ® (buprenorphine) extended-release subcutaneous injection is now available for the treatment of moderate to ...

— Fixed-dose combination administered under the skin in just minutes, compared to hours with intravenous administration, significantly reducing time spent receiving treatment — — Phase III FeDeriCa ...

The FDA approves a new subcutaneous formulation of amivantamab, enhancing treatment for advanced lung cancer with reduced administration time and improved safety.

The US Food and Drug Administration (FDA) has approved the biologics license application for a subcutaneous formulation of lecanemab (Leqembi Iqlik) for weekly maintenance dosing to treat Alzheimer’s ...

Three years after its initial FDA approval, Roche has made up for an early disadvantage with its blood cancer drug Lunsumio ...

Intradermal administration of the JYNNEOS mpox vaccine is as effective and safe as subcutaneous administration, according to new data released this week by the Centers for Disease Control and ...

Basel, 29 June 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the US Food and Drug Administration (FDA) has approved Phesgo™, a fixed-dose combination of Perjeta® (pertuzumab) and ...